CSL Ltd Annual Report 2020

Immunology Research Pre-Clinical Clinical Registration Post-Launch Haegarda ® (C1 Esterase Inhibitor) Subcutaneous in Japan Hizentra ® (20% subcutaneous Ig) Dermatomyositis Hizentra ® (20% subcutaneous Ig) Systemic Sclerosis Privigen ® (10% intravenous Ig) Systemic Sclerosis Garadacimab (Anti-FXIIamAb) Hereditary Angioedema CSL324 (Anti-G-CSFRmAb) Hidradenitis Suppurativa CSL730 (Recombinant Trivalent Human IgG1 Fc Multimer)* Gene Therapy Treatments Primary Immune Deficiency* Haematology Research Pre-Clinical Clinical Registration Post-Launch Idelvion ® (Recombinant rFIX-FP) Haemophilia B Afstyla ® (Recombinant FVIII) Haemophilia A CSL630 (pdFVIII Ruide) CSL200 (CAL-H) Sickle Cell Disease CSL510 Modified Fibrinogen CSL889 (Hemopexin) Sickle Cell Disease CSL888 (Haptoglobin) Subarachnoid Haemorrhage Respiratory Research Pre-Clinical Clinical Registration Post-Launch ZEMAIRA ® /RESPREEZA ® (Alpha1-Proteinase Inhibitor) CSL311 (Anti-Beta CommonmAb) CSL787 (Nebulised Ig) Cardiovascular andMetabolic Research Pre-Clinical Clinical Registration Post-Launch CSL112 (ApoA-1) Acute Coronary Syndrome CSL346 (Anti-VEGFBmAb) Diabetic Kidney Disease Transplant Research Pre-Clinical Clinical Registration Post-Launch CSL842 (C1 Esterase Inhibitor) Refractory Antibody Mediated Rejection CSL964 (Alpha Antitrypsin) Prevention of Graft versus Host Disease CSL964 (Alpha Antitrypsin) Treatment of Graft versus Host Disease* Clazakizumab (Anti-IL-6mAb) Antibody Mediated Rejection CSL040 (Novel Complement Inhibitor) Influenza Vaccines Research Pre-Clinical Clinical Registration Post-Launch AFLURIA ® Quad (Quadrivalent Egg-based Influenza Vaccine) FLUCELVAX ® Quadrivalent (Quadrivalent Cell-based Influenza Vaccine) FLUAD ® Trivalent (Adjuvanted Influenza Vaccine) FLUAD ® Quadrivalent (Adjuvanted Influenza Vaccine) Adjuvanted Cell Culture Influenza Vaccine (aQIVc) Self-amplifying mRNA Influenza Vaccine Outlicensed Programs Research Pre-Clinical Clinical Registration Post-Launch Mavrilimumab (Anti-GM-CSFRmAb) CSL334/ASLAN004 (Anti-IL-13RmAb) Atopic Dermatitis LASN01 (Anti-IL-11RmAb) P. Gingivalis Periodontal Disease COVID-19 Research Pre-Clinical Clinical Registration Post-Launch CSL312 (Anti-FXIIamAb) Acute Lung Injury CSL324 (Anti-G-CSFRmAb) Acute Lung Injury CSL451 (aCoV2)* COVID-19 Hyperimmune Therapy* * Partnered projects. CSL’s pipeline also includes Life Cycle Managment projects that address regulatory post-marketing commitments, pathogen safety, capacity expansions, yield improvements, and new packages and sizes. CSL Limited Annual Report 2020 11